MCID: HMG004
MIFTS: 31

Hemoglobin D Disease malady

Categories: Blood diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Hemoglobin D Disease

Aliases & Descriptions for Hemoglobin D Disease:

Name: Hemoglobin D Disease 12 56 14 69
Hb-D Disease 12

Characteristics:

Orphanet epidemiological data:

56
hemoglobin d disease
Age of onset: Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:5378
ICD10 33 D58.2
NCIt 47 C35344
SNOMED-CT 64 66729008
Orphanet 56 ORPHA90039
UMLS via Orphanet 70 C0272080
ICD10 via Orphanet 34 D58.2
UMLS 69 C0272080

Summaries for Hemoglobin D Disease

MalaCards based summary : Hemoglobin D Disease, also known as hb-d disease, is related to sickle cell - hemoglobin d disease and adult-onset multiple mitochondrial dna deletion syndrome due to dguok deficiency. An important gene associated with Hemoglobin D Disease is HBB (Hemoglobin Subunit Beta), and among its related pathways/superpathways is Factors involved in megakaryocyte development and platelet production. The drugs Heparin and Dopamine have been mentioned in the context of this disorder.

Related Diseases for Hemoglobin D Disease

Graphical network of the top 20 diseases related to Hemoglobin D Disease:



Diseases related to Hemoglobin D Disease

Symptoms & Phenotypes for Hemoglobin D Disease

Drugs & Therapeutics for Hemoglobin D Disease

Drugs for Hemoglobin D Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 708)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
4
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
5
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3 58-22-0 6013
6
Aspirin Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-78-2 2244
7
Quinine Approved Phase 4,Phase 3 130-95-0 8549 3034034
8
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
9
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
10
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1,Phase 2 128794-94-5 5281078
12
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
13
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
14
Copper Approved Phase 4,Phase 2 15158-11-9, 7440-50-8 27099
15
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
16
Selenium Approved, Vet_approved Phase 4,Phase 3,Phase 2 7782-49-2
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2 1197-18-8 5526
19
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
20
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
21
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Rivaroxaban Approved Phase 4 366789-02-8
24
Benzocaine Approved Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
25
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
26
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 5460373 44475014
27
Methyltestosterone Approved Phase 4,Phase 2,Phase 3 58-18-4 6010
28
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
29
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
30
Artemether Approved Phase 4,Phase 3 71963-77-4 119380 68911
31
Insulin Lispro Approved Phase 4,Phase 3,Phase 2 133107-64-9
32
Pancrelipase Approved Phase 4,Phase 2,Phase 1 53608-75-6
33
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757 53477783
35
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
36
Glimepiride Approved Phase 4,Phase 3,Phase 2 93479-97-1 3476
37
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
38
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
39
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
40
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
41
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
42
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
43
Phenprocoumon Approved Phase 4 435-97-2 9908 54680692
44
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
45
Pyrimethamine Approved, Vet_approved Phase 4,Phase 3 58-14-0 4993
46
Sulfadoxine Approved Phase 4,Phase 3 2447-57-6 17134
47
Halofantrine Approved Phase 4 69756-53-2 37393
48
Saxagliptin Approved Phase 4,Phase 3 361442-04-8 11243969
49
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2
50
Ethinyl Estradiol Approved Phase 4 57-63-6 5991

Interventional clinical trials:

(show top 50) (show all 942)
id Name Status NCT ID Phase
1 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
2 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4
3 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4
4 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4
5 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4
6 Diabetes and Depression in Hispanics and African Americans: Treatment of Depression With Sertraline and Its Effect on A1c and Quality of Life Unknown status NCT00624013 Phase 4
7 Iron Supplementation of Marginally Low Birth Weight Infants Unknown status NCT00558454 Phase 4
8 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4
9 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
10 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4
11 Nutrient Fortified Oat Drink Unknown status NCT01418898 Phase 4
12 Different Iron Supplements for Prevention of Anemia in Pregnancy Unknown status NCT02487719 Phase 4
13 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4
14 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4
15 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate Unknown status NCT00555087 Phase 4
16 A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4
17 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
18 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4
19 Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Completed NCT00224055 Phase 4
20 Antithrombotic Triple Therapy in Humans Completed NCT01812200 Phase 4
21 Effect of Omega-3 Fatty Acid on Vitamin D Activation Completed NCT01596842 Phase 4
22 Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso Completed NCT00909974 Phase 4
23 Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4
24 Ticagrelor China Pharmacokinetic/Pharmacodynamic Study Completed NCT02064985 Phase 4
25 The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya Completed NCT00130065 Phase 4
26 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4
27 Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients Completed NCT00819325 Phase 4
28 The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus Completed NCT01608724 Phase 4
29 Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed NCT00965549 Phase 4
30 Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso Completed NCT00642408 Phase 4
31 Safety and Efficacy of Iron Sucrose in Children Completed NCT00239642 Phase 4
32 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) Completed NCT00303602 Phase 4
33 C-Reactive Protein (CRP) in Obese Diabetic Women Completed NCT00262548 Phase 4
34 Study of Erythropoietin (EPO) Administration Schedule Completed NCT01111630 Phase 4
35 Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) Completed NCT00993187 Phase 4
36 Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea Completed NCT01195090 Phase 4
37 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4
38 Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Completed NCT00531947 Phase 4
39 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Completed NCT02471404 Phase 4
40 Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin Completed NCT00802139 Phase 4
41 Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes Completed NCT01427920 Phase 4
42 Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4
43 A Study on the Effect of 2 Pen Devices on HbA1c Completed NCT00985712 Phase 4
44 Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. Completed NCT02157298 Phase 4
45 Blood Management in Orthopedic Surgery Completed NCT00998088 Phase 4
46 Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy Completed NCT00224068 Phase 4
47 Metformin for the Prevention of the Metabolic Side-effects of Zyprexa Completed NCT00682448 Phase 4
48 LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus Completed NCT00423215 Phase 4
49 Locally Delivered Aloe Vera Gel in the Treatment of Chronic Periodontitis Patients With Diabetes Mellitus Completed NCT02437747 Phase 4
50 The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery Completed NCT01235715 Phase 4

Search NIH Clinical Center for Hemoglobin D Disease

Genetic Tests for Hemoglobin D Disease

Anatomical Context for Hemoglobin D Disease

Publications for Hemoglobin D Disease

Articles related to Hemoglobin D Disease:

id Title Authors Year
1
Pulmonary thromboembolism in a child with sickle cell hemoglobin d disease in the setting of acute chest syndrome. ( 24159402 )
2013
2
First report of successful stem cell transplantation in a patient with sickle cell hemoglobin D disease. ( 20502357 )
2010
3
Hematological malignancy in hemoglobin D disease. ( 3162650 )
1988
4
Sickle cell hemoglobin D disease: first reported case in Iran. ( 754514 )
1978
5
The diagnosis of homozygous hemoglobin D disease. ( 5047609 )
1972
6
Hemoglobin D disease: report of a case. ( 5556213 )
1971
7
SICKLE CELL HEMOGLOBIN D DISEASE IN A NEGRO COLOMBIAN PATIENT. ( 14295513 )
1965

Variations for Hemoglobin D Disease

Expression for Hemoglobin D Disease

Search GEO for disease gene expression data for Hemoglobin D Disease.

Pathways for Hemoglobin D Disease

Pathways related to Hemoglobin D Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.82 HBB HBD

GO Terms for Hemoglobin D Disease

Cellular components related to Hemoglobin D Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 8.96 HBB HBD
2 hemoglobin complex GO:0005833 8.8 HBB HBD HBQ1

Biological processes related to Hemoglobin D Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transport GO:0006810 9.33 HBB HBD HBQ1
2 blood coagulation GO:0007596 8.96 HBB HBD
3 oxygen transport GO:0015671 8.8 HBB HBD HBQ1

Molecular functions related to Hemoglobin D Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.43 HBB HBD HBQ1
2 heme binding GO:0020037 9.33 HBB HBD HBQ1
3 oxygen binding GO:0019825 9.13 HBB HBD HBQ1
4 oxygen transporter activity GO:0005344 8.8 HBB HBD HBQ1

Sources for Hemoglobin D Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....